Background： Development of innovative immunotherapy is imperative to improve the poor survival of the nasopharyngeal carcinoma （NPC） patients. In this study, we evaluated the T cell response to melanoma-associated ...Background： Development of innovative immunotherapy is imperative to improve the poor survival of the nasopharyngeal carcinoma （NPC） patients. In this study, we evaluated the T cell response to melanoma-associated antigen （MAGE）-A1, MAGE-A3, or synovial sarcoma X-2 （SSX-2） in the peripheral blood of treatment-naive NPC patients. The relationship of responses among the three proteins and the human leukocyte antigen （HLA）-A types were analyzed to provide evidence of designing novel therapy. Methods： Sixty-one NPC patients admitted into the Tumor Hospital affiliated to the Xinjiang Medical University between March 2015 and July 2016 were enrolled. Mononuclear cells were isolated from the peripheral blood before any treatment. HLA-A alleles were typed with Sanger sequence-based typing technique. The T cell response to the MAGE-A1, MAGE-A3, or SSX-2 was evaluated with the Enzyme-Linked ImmunoSpot assay. Mann-Whitney U-test was used to compare the T cell responses from different groups. Spearman＇s rank correlation was used to analyze the relationship of T cell responses. Results： HLA-A＊02：01, A＊02：07, and A＊24：02 were the three most frequent alleles （18.9%, 12.3%, and 11.5%, respectively） among the 22 detected alleles. 31.1%, 19.7%, and 16.4% of the patients displayed MAGE-A1, MAGE-A3, or SSX-2-specific T cell response, respectively. The magnitudes of response to the three proteins were 32.5, 38.0, and 28.7 SFC/106 peripheral blood mononuclear cells, respectively. The T cell response against the three proteins correlated with each other to different extent. The percentage of A＊02：01 and A＊24：02 carriers were significantly higher in patients responding to any of the three proteins compared to the nonresponders. Conclusion： MAGE-A1, MAGE-A3, or SSX-2-specific T cell responses were detectable in a subgroup of NPC patients, the frequency and magnitude of which were correlated.展开更多
目的检测人脑膜瘤组织中黑色素瘤相关抗原MAGE-D4 m RNA的表达并分析其临床意义。方法采用逆转录-聚合酶链反应(reverse transcription polymerase chain reaction,RT-PCR)方法,检测36例脑膜瘤组织和8例正常人脑组织中MAGE-D4 m RNA的表...目的检测人脑膜瘤组织中黑色素瘤相关抗原MAGE-D4 m RNA的表达并分析其临床意义。方法采用逆转录-聚合酶链反应(reverse transcription polymerase chain reaction,RT-PCR)方法,检测36例脑膜瘤组织和8例正常人脑组织中MAGE-D4 m RNA的表达,分析MAGE-D4 m RNA的表达与脑膜瘤患者临床病理特征的关系。结果 MAGE-D4 m RNA在脑膜瘤组织中的阳性表达率为58.33%(21/36),明显高于正常人脑组织中的阳性表达率12.50%(1/8)(P<0.05);脑膜瘤组织中MAGE-D4 m RNA的表达与性别、年龄、肿瘤大小和病理类型等临床病理特征无关(P>0.05)。结论在脑膜瘤组织中MAGE-D4的表达率较高,提示MAGE-D4可能成为脑膜瘤免疫治疗的靶抗原。展开更多
文摘Background： Development of innovative immunotherapy is imperative to improve the poor survival of the nasopharyngeal carcinoma （NPC） patients. In this study, we evaluated the T cell response to melanoma-associated antigen （MAGE）-A1, MAGE-A3, or synovial sarcoma X-2 （SSX-2） in the peripheral blood of treatment-naive NPC patients. The relationship of responses among the three proteins and the human leukocyte antigen （HLA）-A types were analyzed to provide evidence of designing novel therapy. Methods： Sixty-one NPC patients admitted into the Tumor Hospital affiliated to the Xinjiang Medical University between March 2015 and July 2016 were enrolled. Mononuclear cells were isolated from the peripheral blood before any treatment. HLA-A alleles were typed with Sanger sequence-based typing technique. The T cell response to the MAGE-A1, MAGE-A3, or SSX-2 was evaluated with the Enzyme-Linked ImmunoSpot assay. Mann-Whitney U-test was used to compare the T cell responses from different groups. Spearman＇s rank correlation was used to analyze the relationship of T cell responses. Results： HLA-A＊02：01, A＊02：07, and A＊24：02 were the three most frequent alleles （18.9%, 12.3%, and 11.5%, respectively） among the 22 detected alleles. 31.1%, 19.7%, and 16.4% of the patients displayed MAGE-A1, MAGE-A3, or SSX-2-specific T cell response, respectively. The magnitudes of response to the three proteins were 32.5, 38.0, and 28.7 SFC/106 peripheral blood mononuclear cells, respectively. The T cell response against the three proteins correlated with each other to different extent. The percentage of A＊02：01 and A＊24：02 carriers were significantly higher in patients responding to any of the three proteins compared to the nonresponders. Conclusion： MAGE-A1, MAGE-A3, or SSX-2-specific T cell responses were detectable in a subgroup of NPC patients, the frequency and magnitude of which were correlated.
文摘目的检测人脑膜瘤组织中黑色素瘤相关抗原MAGE-D4 m RNA的表达并分析其临床意义。方法采用逆转录-聚合酶链反应(reverse transcription polymerase chain reaction,RT-PCR)方法,检测36例脑膜瘤组织和8例正常人脑组织中MAGE-D4 m RNA的表达,分析MAGE-D4 m RNA的表达与脑膜瘤患者临床病理特征的关系。结果 MAGE-D4 m RNA在脑膜瘤组织中的阳性表达率为58.33%(21/36),明显高于正常人脑组织中的阳性表达率12.50%(1/8)(P<0.05);脑膜瘤组织中MAGE-D4 m RNA的表达与性别、年龄、肿瘤大小和病理类型等临床病理特征无关(P>0.05)。结论在脑膜瘤组织中MAGE-D4的表达率较高,提示MAGE-D4可能成为脑膜瘤免疫治疗的靶抗原。
